Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sophia GeneticsSTU:90B +1.21%55 EBIT per Share is €-0.93 as of Mar. 2026. GuruFocus rates STU:90B with a GF Score™ of 55/100 and a GF Value™ of €4.39 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Sophia Genetics ranks worse than 54.94% on this metric.
Sophia Genetics's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.21.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.93.
During the past 3 years, the average EBIT per Share Growth Rate was 8.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -1.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sophia Genetics's EBIT per Share or its related term are showing as below:
STU:90B'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -26.8 Med: -3.05 Max: 8.5
Current: 8.5
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Sophia Genetics was 8.50% per year. The lowest was -26.80% per year. And the median was -3.05% per year.
STU:90B's 3-Year EBIT Growth Rate is ranked worse than 54.94% of 526
companies
in the Healthcare Providers & Services industry
Industry Median: 12.05
vs STU:90B: 8.50
Sophia Genetics's EBIT for the
three
months ended in Mar. 2026 was €-15.05 Mil.
Sophia Genetics (STU:90B) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sophia Genetics EBIT per Share Related Terms
Sophia Genetics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.93
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics (STU:90B) has a EBIT per Share of €-0.93 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sophia Genetics and its competitors. According to the industry distribution chart, Sophia Genetics ranks #289 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 54.9%.
Is Sophia Genetics' EBIT per Share too high?
Sophia Genetics' current EBIT per Share is €-0.93. Based on the distribution chart, Sophia Genetics ranks #289 out of 526 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Sophia Genetics has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' EBIT per Share compare to WEAV and NRC?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #289 out of 526 companies for EBIT per Share. This places Sophia Genetics in the lower half of its industry. The industry median EBIT per Share is 12.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current EBIT per Share is €-0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (STU:90B) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.39, compared to a current price of €5.00 — trading 13.9% above its estimated fair value. The current EBIT per Share is €-0.93. Sophia Genetics' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sophia Genetics (STU:90B), the current EBIT per Share is €-0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (STU:90B) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of €5.00 is trading 13.9% above its estimated GF Value™ of €4.39.
GuruFocus considers Sophia Genetics to be Modestly Overvalued.
Key valuation signals for STU:90B:
EBIT per Share: €-0.93
GF Value™: €4.39 vs. price of €5.00 (13.9% above fair value)
No single metric tells the full story. See the STU:90B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
55GF Score
Get the complete analysis for STU:90B
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:90B has been successfully added to your 
